NO154346C - Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater.

Info

Publication number
NO154346C
NO154346C NO784397A NO784397A NO154346C NO 154346 C NO154346 C NO 154346C NO 784397 A NO784397 A NO 784397A NO 784397 A NO784397 A NO 784397A NO 154346 C NO154346 C NO 154346C
Authority
NO
Norway
Prior art keywords
phtalazin
preparation
acetic acid
acid derivatives
therapeutically active
Prior art date
Application number
NO784397A
Other languages
English (en)
Other versions
NO154346B (no
NO784397L (no
Inventor
David Robert Brittain
Robin Wood
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of NO784397L publication Critical patent/NO784397L/no
Publication of NO154346B publication Critical patent/NO154346B/no
Publication of NO154346C publication Critical patent/NO154346C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO784397A 1977-12-29 1978-12-28 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater. NO154346C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5414277 1977-12-29

Publications (3)

Publication Number Publication Date
NO784397L NO784397L (no) 1979-07-02
NO154346B NO154346B (no) 1986-05-26
NO154346C true NO154346C (no) 1986-09-03

Family

ID=10470067

Family Applications (1)

Application Number Title Priority Date Filing Date
NO784397A NO154346C (no) 1977-12-29 1978-12-28 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater.

Country Status (31)

Country Link
US (2) US4251528A (no)
EP (1) EP0002895B1 (no)
JP (2) JPS5495582A (no)
AT (1) AT365581B (no)
AU (1) AU516264B2 (no)
BG (1) BG34336A3 (no)
CA (1) CA1107732A (no)
CS (1) CS241015B2 (no)
CY (1) CY1219A (no)
DD (1) DD141021A5 (no)
DE (1) DE2861170D1 (no)
DK (1) DK151253C (no)
ES (1) ES476496A1 (no)
FI (1) FI64357C (no)
GR (1) GR65303B (no)
HK (1) HK22484A (no)
HU (1) HU182585B (no)
IE (1) IE47592B1 (no)
IL (1) IL56099A0 (no)
IN (1) IN150196B (no)
IT (1) IT1110885B (no)
MY (1) MY8500359A (no)
NO (1) NO154346C (no)
NZ (1) NZ189034A (no)
PH (1) PH15435A (no)
PL (1) PL118443B1 (no)
PT (1) PT68956A (no)
SG (1) SG68683G (no)
SU (3) SU1087075A3 (no)
YU (3) YU41607B (no)
ZW (1) ZW24978A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
CA1143733A (en) * 1979-07-31 1983-03-29 Masao Yoshida Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
DE3684410D1 (de) * 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
US5011840A (en) * 1986-11-24 1991-04-30 Pfizer Inc. Imidazolidinedione derivatives in diabetes treatment
GB8704569D0 (en) * 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
EP0315249A1 (en) * 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
US4880928A (en) * 1987-12-21 1989-11-14 Merck & Co., Inc. Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid
US4940791A (en) * 1988-02-29 1990-07-10 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
EP0397930A1 (en) * 1989-05-18 1990-11-22 Merck & Co. Inc. Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
WO1991009019A1 (en) * 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FR2682108B1 (fr) * 1991-10-07 1994-01-07 Lipha Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant.
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
WO1994010151A1 (en) * 1992-11-02 1994-05-11 Merck & Co., Inc. Substituted phthalazinones as nerotensin antagonists
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
AU7195594A (en) * 1993-07-26 1995-02-20 Fujisawa Pharmaceutical Co., Ltd. Oxophthalazines for treating cachexia
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
AU6473898A (en) * 1997-03-21 1998-10-20 Regents Of The University Of California, The Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
JP3553086B2 (ja) * 1997-04-15 2004-08-11 シーエスアイアール 食欲抑制活性を有する医薬組成物
OA11622A (en) * 1998-03-31 2004-09-16 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EA200300433A1 (ru) * 2000-11-30 2003-10-30 Пфайзер Продактс Инк. Комбинация гамк-агонистов и ингибиторов альдегидредуктазы
EP1236720B1 (en) 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
ATE348100T1 (de) 2001-03-30 2007-01-15 Pfizer Prod Inc Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren.
HUP0303920A3 (en) * 2001-04-30 2004-07-28 Pfizer Prod Inc Pharmaceutical compositions containing combinations of aldose reductase inhibitor pyridazinons and cyclooxygenase 2 inhibitors
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
WO2003092696A1 (en) * 2002-04-30 2003-11-13 Novartis Ag Method for decreasing capillary permeability in the retina
KR20050026002A (ko) * 2002-07-26 2005-03-14 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산 유도체 및 이를 함유하는 당뇨 합병증치료용 제형
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
JP4838582B2 (ja) * 2004-12-27 2011-12-14 岐阜プラスチック工業株式会社 台車用本体
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
EP2848252A3 (en) 2007-03-23 2015-06-17 The Board of Regents of the University of Texas System Aldose reductase inhibitors for use in treating uveitis
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
EP2654749B1 (en) 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Methods for treating copd
CA2895162C (en) * 2012-12-14 2021-03-09 D. Lynn Kirkpatrick Methods and compositions for inhibiting cnksr1
CA2983260C (en) 2015-04-20 2024-01-23 Phusis Therapeutics, Inc. Sulfonamide compounds, compositions and methods for inhibiting cnksr1
WO2020071386A1 (ja) * 2018-10-04 2020-04-09 日東電工株式会社 耐熱離型シート及び熱圧着方法
JP6751974B1 (ja) * 2019-10-16 2020-09-09 株式会社コバヤシ 離型フィルム及び離型フィルムの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833579A (en) * 1935-11-11 1974-09-03 Inoue Michiro 4-carbamoyl phthalazones
JPS5116430B2 (no) * 1971-08-05 1976-05-24
GB1398549A (en) * 1972-11-06 1975-06-25 Boots Co Ltd Phthalazine derivatives and their use in pharmaceutical compo sitions
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
DE2451117A1 (de) * 1973-10-31 1975-05-22 Boots Co Ltd Therapeutisch wirksame verbindungen
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
JPS5214788A (en) * 1975-07-21 1977-02-03 Fuji Photo Film Co Ltd Process for preparing phthalazinone and its derivatives
NL7702763A (nl) * 1976-03-18 1977-09-20 Takio Shimamoto En Masayuki Is Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten.
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4293553A (en) * 1978-08-11 1981-10-06 Masayuki Ishikawa 1-Phthalazone derivatives, and use thereof

Also Published As

Publication number Publication date
YU41607B (en) 1987-12-31
GR65303B (en) 1980-08-01
PH15435A (en) 1983-01-18
PL118443B1 (en) 1981-10-31
SG68683G (en) 1984-08-03
NO154346B (no) 1986-05-26
JPS63119469A (ja) 1988-05-24
AU516264B2 (en) 1981-05-28
US4393062A (en) 1983-07-12
IL56099A0 (en) 1979-01-31
YU232182A (en) 1983-01-21
DK151253C (da) 1988-05-16
DE2861170D1 (en) 1981-12-24
JPS6326110B2 (no) 1988-05-27
DD141021A5 (de) 1980-04-09
YU232082A (en) 1983-01-21
SU1272984A3 (ru) 1986-11-23
HK22484A (en) 1984-03-23
FI64357C (fi) 1983-11-10
US4251528A (en) 1981-02-17
SU1087075A3 (ru) 1984-04-15
ES476496A1 (es) 1979-04-16
EP0002895A1 (en) 1979-07-11
YU42054B (en) 1988-04-30
CS241015B2 (en) 1986-03-13
FI64357B (fi) 1983-07-29
NZ189034A (en) 1981-11-19
JPS5495582A (en) 1979-07-28
IE47592B1 (en) 1984-05-02
CA1107732A (en) 1981-08-25
PT68956A (en) 1979-01-01
SU1072803A3 (ru) 1984-02-07
FI783844A (fi) 1979-06-30
AU4204078A (en) 1979-07-05
IE782337L (en) 1979-06-29
ZW24978A1 (en) 1980-10-22
HU182585B (en) 1984-02-28
MY8500359A (en) 1985-12-31
IN150196B (no) 1982-08-14
EP0002895B1 (en) 1981-10-14
IT7852480A0 (it) 1978-12-28
NO784397L (no) 1979-07-02
ATA937678A (de) 1981-06-15
CY1219A (en) 1984-04-06
DK151253B (da) 1987-11-16
BG34336A3 (en) 1983-08-15
AT365581B (de) 1982-01-25
YU312778A (en) 1983-01-21
IT1110885B (it) 1986-01-06
YU42807B (en) 1988-12-31
DK541878A (da) 1979-06-30
JPH0262532B2 (no) 1990-12-26

Similar Documents

Publication Publication Date Title
NO154346C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater.
NO156611C (no) Analogifremgangsmaate for fremstilling av terapeutiske virksomme derivater av hydroksykarbonylfosfonsyre.
NO153177C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive tetrazolylalkoksy-karbostyrilderivater.
NO151966C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme imidazol-5-eddiksyrederivater
NO145915C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive karboksyalkylacylaminosyrer
NO151321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater
NO151463C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolinderivater
NO147450C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolonderivater
NO153136C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive naftyridinderivater.
NO148813C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive karbostyrilderivater
NO152935C (no) Analogifremgangsmaate for fremstilling av anti-inflammatorisk virksomme tioetiansyrederivater.
NO159019C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive 6beta-hydroksyalkylpenicillansyrederivater.
NO154522C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme kinolinderivater.
NO153569C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive merkaptoacetyl-prolin-derivater.
NO145379C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n2-arylsulfonyl-l-argininamider.
NO148777C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antrakinon-derivater
NO146095C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinazolin-derivater
NO152654C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive derivater av 7-acylamido-3-cephem-4-karboksylsyre
NO802087L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karboksylsyrederivater
NO151500C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazoloksamsyre-derivater
NO781878L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner.
NO151285C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive di-o-n-alkyl-glycerolderivater
NO148454C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidin-dionderivater
NO151660C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater.
NO780644L (no) Fremgangsmaate til fremstilling av terapeutisk virksomme 9-hydroksyetoksymetylguanin-derivater